Discussing out-of-pocket costs with patients: Shared decision making for Sacubitril-Valsartan in heart failure

Journal of the American Heart Association

Volumn 8, Issue 1, 2019, Pages

  Smith, Graham H ^a   Shore, Supriya ^b   Allen, Larry A ^c   Markham, David W ^a   Mitchell, Andrea R ^a   Moore, Miranda ^a   Morris, Alanna A ^a   Speight, Candace D ^a   Dickert, Neal W ^a,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Cost; Ethics; Heart failure; Shared decision making

Indexed keywords

SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; SACUBITRIL-VALSARTAN; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DRUG COST; FEMALE; HEALTH CARE COST; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; INCOME; MALE; OUT OF POCKET COST; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROBABILITY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SHARED DECISION MAKING; COST BENEFIT ANALYSIS; ECONOMICS; HEART FAILURE; MIDDLE AGED; QUALITY ADJUSTED LIFE YEAR; UNITED STATES;

ADULT; AGED; AMINOBUTYRATES; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DECISION MAKING, SHARED; DRUG COSTS; FEMALE; HEALTH EXPENDITURES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; TETRAZOLES; UNITED STATES;

EID: 85059237299     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.118.010635     Document Type: Article

References (20)

1. Bestvina CM, Zullig LL, Rushing C, Chino F, Samsa GP, Altomare I, Tulsky J, Ubel P, Schrag D, Nicolla J, Abernethy AP, Peppercorn J, Zafar SY. Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract. 2014;10:162–167.
2. Alexander GC, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. JAMA. 2003;290:953–958.
3. Ubel PA, Abernethy AP, Zafar SY. Full disclosure—out-of-pocket costs as side effects. N Engl J Med. 2013;369:1484–1486.
4. Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, Abernethy AP. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist. 2013;18:381–390.
5. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497.
6. Richman IB, Brodie M. A national study of burdensome health care costs among non elderly Americans. BMC Health Serv Res. 2014;14:435.
7. Dayoub EJ, Seigerman M, Tuteja S, Kobayashi T, Kolansky DM, Giri J, Groeneveld PW. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008–2016. JAMA Intern Med. 2018;178:943–950.
8. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
9. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;134:e282–e293.
10. Grainger D. Is the superiority of entresto just an illusion? Forbes. http://www.forbes.com/sites/davidgrainger/2015/09/14/is-the-superiority-of-entresto-just-an-illusion/#647ee2770a4f. Accessed February 10, 2017.
11. Allen LA, Fonarow GC, Liang L, Schulte PJ, Masoudi FA, Rumsfeld JS, Ho PM, Eapen ZJ, Hernandez AF, Heidenreich PA, Bhatt DL, Peterson ED, Krumholz HM. Medication initiation burden required to comply with heart failure guideline recommendations and hospital quality measures. Circulation. 2015;132:1347–1353.
12. Janssen B, Szende A, Cabases J, eds. Self-Reported Population Health: An International Perspective Based on EQ-5D. New York, NY: Springer; 2014.
13. Wallace LS, Rogers ES, Roskos SE, Holiday DB, Weiss BD. Brief report: screening items to identify patients with limited health literacy skills. J Gen Intern Med. 2006;21:874–877.
14. Coylewright M, Dick S, Zmolek B, Askelin J, Hawkins E, Branda M, Inselman JW, Zeballos-Palacios C, Shah ND, Hess EP, LeBlanc A, Montori VM, Ting HH. PCI choice decision aid for stable coronary artery disease: a randomized trial. Circ Cardiovasc Qual Outcomes. 2016;9:767–776.
15. Hess EP, Knoedler MA, Shah ND, Kline JA, Breslin M, Branda ME, Pencille LJ, Asplin BR, Nestler DM, Sadosty AT, Stiell IG, Ting HH, Montori VM. The chest pain choice decision aid: a randomized trial. Circ Cardiovasc Qual Outcomes. 2012;5:251–259.
16. Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000;23:334–340.
17. Cassell C. Template Analysis: The SAGE Dictionary of Qualitative Management Research. London, England: Sage Publications; 2008.
18. Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes. 2010;8:13.
19. Gorin M, Joffe S, Dickert N, Halpern S. Justifying clinical nudges. Hastings Cent Rep. 2017;47:32–38.
20. Luo N, Fonarow GC, Lippmann SJ, Mi X, Heidenreich PA, Yancy CW, Greiner MA, Hammill BG, Hardy NC, Turner SJ, Laskey WK, Curtis LH, Hernandez AF, Mentz RJ, O’Brien EC. Early adoption of sacubitril/valsartan for patients with heart failure with reduced ejection fraction: insights from get with the guidelines heart failure (GWTG-HF). JACC Heart Fail. 2017;5:305–309.